Paul Ehrlich's magic bullet concept: 100 years of progress
Top Cited Papers
- 12 May 2008
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 8 (6), 473-480
- https://doi.org/10.1038/nrc2394
Abstract
Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.Keywords
This publication has 102 references indexed in Scilit:
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencingNature Medicine, 2006
- Towards a proteome-scale map of the human protein–protein interaction networkNature, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- The Hallmarks of CancerCell, 2000
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957